MEDPLUS

MedPlus Health Services Limited July 21, 2026 The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Dalal Street, Fort, Bandra Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai – 400 051 BSE Scrip Code: 543427 NSE Symbol: MEDPLUS Dear Sir/ Madam, Sub: Presentation for Earnings Call with Analysts/Institutional Investors on Un-Audited Financial Results for the quarter ended June 30, 2026 Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to our letter dated July 15, 2026 please find enclosed herewith the presentation for Earnings Call with Analysts/Institutional Investors on Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 scheduled to be held on Wednesday, July 22, 2026 at 16:00 Hrs. (IST). The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively. Thanking You Yours faithfully For MedPlus Health Services Limited Gangadi Madhukar Reddy Managing Director and CEO (DIN: 00098097) Encl: a/a 040-6724 6724 Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com FY27 Q1 Executive Summary ➢ Revenue has grown by 21.8% from ₹ 15,426 million in Q1 FY26 to ₹ 18,796 million in Q1 FY27 ➢ During the quarter 146 new stores have been added (including 131 new franchisees) ➢ Gross margin decreased by 160 bps from 26.1% in Q1 FY26 to 24.5% in Q1 FY27 ➢ Operating EBITDA has decreased from ₹ 728 million in Q1 FY26 to ₹ 651 million in Q1 FY27 ➢ Operating EBITDA margin for Q1 FY27 has decreased by 120 bps YoY from 4.7% to 3.5% ➢ AOP vs Actual – Revenue ₹ 18,796 million / ₹ 18,993 million (99.0% achievement) ➢ AOP vs Actual – Op. EBITDA ₹ 651 million / ₹ 798 million (81.6% achievement) 1 Income Statement : All Segments ₹m Q1 FY27 AOP Particulars Q1 FY27 Q1 FY26 Q4 FY26 YoY QoQ AOP Variance Revenue 18,796.0 15,426.3 18,643.8 18,993.5 21.8% 0.8% -1.0% - Revenue for Q1FY27 has grown by 21.8% YoY and QoQ has grown by 0.8% Gross Margin 4,603.1 4,029.0 4,934.4 4,913.9 14.3% -6.7% -6.3% Gross Margin% 24.5% 26.1% 26.5% 25.9% -1.6% -2.0% -1.4% - Gross margin % decreased by 160 bps YoY from 26.1% in Q1FY26 to 24.5% in Q1FY27 Shoplevel Expenses 2,695.7 2,365.4 2,595.4 2,817.7 14.0% 3.9% -4.3% Salaries 1,221.5 941.2 1,120.6 1,248.0 29.8% 9.0% -2.1% - Gross margin % decreased by 200 bps QoQ from 26.5% in Q4FY26 to 24.5% in Q1FY27 Rent 609.5 532.3 588.6 620.6 14.5% 3.5% -1.8% Others 864.7 891.9 886.1 949.1 -3.0% -2.4% -8.9% - Operating EBITDA Margin decreased by 130 bps YoY from 4.7% in Q1FY26 to 3.5% in Q1FY27 Shoplevel EBITDA 1,907.4 1,663.6 2,339.0 2,096.1 14.7% -18.5% -9.0% Shoplevel EBITDA% 10.1% 10.8% 12.5% 11.0% -0.6% -2.4% -0.9% - Operating EBITDA Margin decreased by 230 bps QoQ from 5.8% in Q4FY26 to 3.5% in Q1FY27 Other Expenses 1,256.2 935.5 1,262.7 1,298.0 34.3% -0.5% -3.2% PSD 794.5 583.4 751.3 786.3 36.2% 5.8% 1.0% Corporate 413.5 347.5 474.2 459.6 19.0% -12.8% -10.0% Marketing 16.8 15.8 29.3 30.0 6.0% -42.8% -44.1% Others 31.4 (11.3) 8.0 22.1 -378.9% 295.3% 42.1% Operating EBITDA 651.2 728.1 1,076.3 798.1 -10.6% -39.5% -18.4% Operating EBITDA% 3.5% 4.7% 5.8% 4.2% -1.3% -2.3% -0.7% EBITDA 1,530.7 1,457.6 1,897.7 1,647.9 5.0% -19.3% -7.1% PBT 418.8 527.8 803.4 536.7 -20.7% -47.9% -22.0% PBT% 2.2% 3.4% 4.3% 2.8% -1.2% -2.1% -0.6% PAT 331.7 423.5 639.7 401.7 -21.7% -48.2% -17.4% PAT% 1.8% 2.7% 3.4% 2.1% -1.0% -1.7% -0.4% 2 Income Statement : Pharmacy ₹m Q1 FY27 AOP Particulars Q1 FY27 Q1 FY26 Q4 FY26 YoY QoQ AOP Variance - Revenue for Q1FY27 has grown by 21.8% YoY and QoQ Revenue 18,398.7 15,106.4 18,265.9 18,599.6 21.8% 0.7% -1.1% has grown by 0.7% Gross Margin 4,282.0 3,772.6 4,627.5 4,597.2 13.5% -7.5% -6.9% - Gross margin % decreased by 170 bps YoY from 25.0% in Q1FY26 to 23.3% in Q1FY27. Gross Margin% 23.3% 25.0% 25.3% 24.7% -1.7% -2.1% -1.4% - Decrease of 120 bps is due to lower sales mix of Private Label products and Shoplevel Expenses 2,498.0 2,201.3 2,403.6 2,616.2 13.5% 3.9% -4.5% - Decrease of 50 bps is due to lower margin realized Salaries 1,149.8 887.8 1,050.7 1,173.9 29.5% 9.4% -2.1% in franchisee business Rent 572.3 503.1 551.9 583.6 13.7% 3.7% -1.9% Others 775.9 810.4 801.1 858.6 -4.3% -3.1% -9.6% - Gross margin % decreased by 210 bps QoQ from 25.3% in Q4FY26 to 23.3% in Q1FY27 - Decrease of 100 bps is due to lower sales mix of Shoplevel EBITDA 1,784.1 1,571.3 2,223.9 1,981.1 13.5% -19.8% -9.9% Private Label products Shoplevel EBITDA% 9.7% 10.4% 12.2% 10.7% -0.7% -2.5% -1.0% - Decrease of 70 bps is due to lower inventory loss in the previous quarter Other Expenses 1,196.0 881.1 1,202.0 1,220.6 35.7% -0.5% -2.0% - Decrease of 40 bps is due to year end related PSD 761.7 554.0 719.2 745.1 37.5% 5.9% 2.2% supplier discounts received in the previous quarter Corporate 389.0 326.4 449.0 429.0 19.2% -13.4% -9.3% - Operating EBITDA Margin decreased by 140 bps YoY from Marketing 13.4 12.0 25.6 25.0 11.6% -47.4% -46.2% 4.6% in Q1FY26 to 3.2% in Q1FY27 Others 31.9 ( 11.3) 8 .3 21.6 -382.8% 284.5% 47.8% - Operating EBITDA Margin decreased by 240 bps QoQ Operating EBITDA 588.1 690.1 1,021.8 760.4 -14.8% -42.4% -22.7% from 5.6% in Q4FY26 to 3.2% in Q1FY27 Operating EBITDA% 3.2% 4.6% 5.6% 4.1% -1.4% -2.4% -0.9% 3 Revenue by category ₹ million Particulars FY25Q1 FY25Q2 FY25Q3 FY25Q4 FY25 FY26Q1 FY26Q2 FY26Q3 FY26Q4 FY26 FY27Q1 Branded Pharma 10,333 10,594 10,330 9,543 40,800 9 ,987 10,736 11,245 11,598 43,566 11,981 Branded Non Pharma 1,672 1,679 1,620 1,424 6 ,395 1 ,421 1,463 1,627 1,634 6 ,146 1 ,665 Pvt Label Pharma 1,357 1,663 1,774 2,043 6 ,837 1 ,976 2,031 2,101 2,115 8 ,223 2 ,009 Pvt Label Non Pharma 1,004 1,240 1,291 1,463 4 ,997 1 ,347 1,621 1,908 1,979 6 ,855 1 ,754 Total 14,366 15,176 15,014 14,473 59,029 14,731 15,850 16,882 17,326 64,790 17,409 Franchisee and B2B 126 138 145 146 555 224 379 580 722 1 ,905 859 Others1 137 146 166 179 628 152 210 253 217 832 130 Grand Total 14,629 15,460 15,325 14,798 60,212 15,106 16,440 17,715 18,266 67,527 18,399 Others mainly include - Membership fee of Rs.97.6 million in FY27 Q1 (Rs.87.2 million in FY26 Q4) - Other charges collected Rs.9.0 million in FY27 Q1 (Rs.8.4 million in FY26 Q4) Category Mix (Net Sales) Particulars FY25Q1 FY25Q2 FY25Q3 FY25Q4 FY25 FY26Q1 FY26Q2 FY26Q3 FY26Q4 FY26 FY27Q1 Branded Pharma 71.9% 69.8% 68.8% 65.9% 69.1% 67.8% 67.7% 66.6% 66.9% 67.2% 68.8% Branded Non Pharma 11.6% 11.1% 10.8% 9.8% 10.8% 9.6% 9.2% 9.6% 9.4% 9.5% 9.6% Pvt Label Pharma 9.4% 11.0% 11.8% 14.1% 11.6% 13.4% 12.8% 12.4% 12.2% 12.7% 11.5% Pvt Label Non Pharma 7.0% 8.2% 8.6% 10.1% 8.5% 9.1% 10.2% 11.3% 11.4% 10.6% 10.1% Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 1. Others include Membership fee, Data fee, display income, etc. 4 Market Estimates vs Performance ₹ million Axis Cap Nuvama Spark HDFC Sec Elara Cap MedPlus Revenue 1 8,512.0 18,203.0 18,737.0 18,510.0 18,112.0 18,796.0 Cost of sales 14,192.9 Gross Profit 4,603.1 Gross Margin % 24.5% Op.EBITDA 608.0 651.2 Op.EBITDA % 3.3% 3.1% 3.5% EBITDA 1,204.0 1,264.0 1,203.0 1,600.0 1,332.4 EBITDA margin 6.5% 6.9% 6.5% 8.8% 7.1% PBT 334.0 418.8 PAT 2 26.0 316.0 260.0 204.0 537.0 331.7 5 Network of 5,476 Pharmacies1… 5600 - Network of stores as on 30th June 2026 is 146 5476 5,476 (COCO stores 4,812 and Franchisee stores 664) 5400 218 5330 - Net addition of 146 stores in Q1FY27 5200 (Q1FY26 101) 182 - Operating in 850+ Cities and towns, covering 5000 Kolkata 315 117 1 2,520+ PIN codes 101 4800 1 - Total Retail area is 2.9 Mn Sft with average 4712 store size is 528 Sft 4600 48 758 - Average area of the stores opened in Q1FY27 is 539 Sft 4400 55 189 620 - In addition to the pharmacies, company is Bhubaneswar 64 4200 operating 30 optical counters 912 Hyderabad 519 - In Q1FY27 we have closed 52 stores out of 686 4000 1040 which Mar-25 FY26Q1 FY26Q2 FY26Q3 FY26Q4 Mar-26 FY27Q1 Jun-26 Visakhapatnam 67, - Relocations are 9 Vijayawada 68 - Franchisee withdrawn are 27 1118 - Others are 16 due to performance Net Additions Pune 135 Bangalore 439 41 issues, landlord issues and others like Nagpur 103 City Category FY27Q1 Mumbai 61 road widening/blockage/visibility Chennai 472 Metro -1 - Another 24 stores are in the process of Tier-1 34 conversion from COCO stores to Franchisee Tier-2 57 stores Powered by Bing Tier-3 56 © GeoNames, Microsoft, TomTom Total 146 - Average age of the closed stores is 4 years Beyond Tier-2 77% 1. Including Franchisee Stores 6 Q1 FY27 Performance by Cohort # Pharmacies Revenue, ₹m Store EBITDA, ₹m 112, 2% 1031, 6% 132, 1% 19, 1% -18, -1% 62, 4% 442, 9% 879, 5% 3321, 13936, 143, 8% 1499, 335, 7% 69% 1563, 79% 86% 9% 602, 13% UptoFY23 FY24 FY25 FY26 FY27 Upto FY23 FY24 FY25 FY26 FY27 Upto FY23 FY24 FY25 FY26 FY27 Cohort Stores# Revenue1 Store EBITDA Store EBITDA% UptoFY23 3,321 13,935.6 1,498.7 10.8% FY24 6 02 1,562.5 143.4 9.2% FY25 3 35 878.6 61.5 7.0% FY26 4 42 1,031.0 19.0 1.8% FY27 1 12 131.6 (17.9) -13.6% Total 4,812 17,539.3 1,704.8 9.7% Others2 6 64 859.4 79.3 9.2% Grand Total 5,476 18,398.7 1,784.1 9.7% 1. Revenue includes Membership fee, Data fee, display income, etc. 2. Includes Franchisee and B2B business 7 Pharmacy EBITDA – Q1 FY27 (Cause of change) Operating EBITDA YoY, ₹m Operating EBITDA QoQ, ₹m 1,100 509 1,022 1,000 900 -297 800 690 700 -208 -345 12 60 600 -63 -1 588 588 -43 -94 -24 -43 500 400 300 - Operating EBITDA margin decreased by ~14% YoY from 4.6% to 3.2% - Operating EBITDA margin decreased by ~42% QoQ from 5.6% to 3.2% - Gross Margin decrease - Gross Margin decrease - Decrease of 120 bps is due to lower sales mix of Private Label - Decrease of 100 bps is due to lower sales mix of Private Label products products and - Decrease of 70 bps is due to lower inventory loss in the previous quarter - Decrease of 50 bps is due to lower margin realized in franchisee - Decrease of 40 bps is due to year end related supplier discounts business. received in the previous quarter 8 COCO Stores: 4,812 Stores Revenue, ₹m PL Mix% 17,326 17,409 16,882 24.2% 15,176 15,014 14,473 14,731 15,850 22.6% 23.0% 23.8% 23.6% 21.6% 20.4% 19.1% 10.1% 9.1% 10.2% 11.3% 11.4% 8.6% 10.1% 8.2% 11.0% 11.8% 14.1% 13.4% 12.8% 12.4% 12.2% 11.5% PL P% PL NP% PL% Slab wise Bills in Thousands Slab wise Revenue mix 41,893 42,223 40,757 40,117 43,797 45,772 45,169 43,717 6,642 6,561 6,440 6,557 6,916 7,224 7,425 7,172 14,085 14,471 14,151 13,989 15,217 16,193 16,286 16,239 63.2% 62.2% 62.6% 63.7% 62.5% 61.9% 62.9% 62.9% 21,166 21,191 20,166 19,570 21,664 22,354 21,458 20,305 28.5% 29.4% 29.2% 28.6% 29.3% 29.9% 29.4% 29.9% 8.3% 8.4% 8.2% 7.7% 8.2% 8.2% 7.7% 7.3% 0-200 200-1000 >1000 Total 0-200 200-1000 >1000 9 COCO Stores: 4,812 Stores Store Level EBITDA and EBITDA% Gross Margin & Discount 12.6% 12.0% 11.5% 11.2% 2,177 10.5% 10.5% 27.1% 27.3% 26.8% 9.8% 2,028 9.8% 26.4% 26.0% 25.9% 1,817 1,582 1,616 1,551 1,705 - SL EBITDA 9.8% in FY27Q1 (PY:10.5%) 1,486 24.2% - Out of 2,658 stores which are below 9.8% 23.4% - 1406 stores have less than 5% 26.4% 26.0% 25.5% 25.7% 25.9% EBITDA 24.4% 24.1% - 674 stores are having 5-8% EBITDA 23.0% - Upto FY23 cohort has 242 loss making stores out of 3,321 stores Margin% Discount% SL EBITDA SL EBITDA% - FY24 cohort has 87 loss making stores out of 602 stores Store Inventory ₹m & Inventory Days Stores# Above & Below Avg EBITDA% 45 40 42 42 41 40 39 37 7,230 7,503 7,587 1,809 1,844 1,859 1,904 1,934 1,964 2,101 2,154 6,968 6,786 6,636 6,807 6,808 3,003 2,968 2,953 2,908 2,878 2,848 2,711 2,658 Below Avg Above Avg Inventory Inventory Days 10 COCO Stores: 4,812 Stores SSSG ₹ million Revenue by category: Up to FY23 Cohort ₹ million 11 C U F F F F C G P B B P P T o h o r t p t o F Y 2 Y 2 4 Y 2 5 Y 2 6 Y 2 7 l o s e d / C r a n d T o a r t i c u l a r a n d e d r a n d e d v t L a b e v t L a b e o t a l 3 o n v e r t a l r s P h a r m N o n - P l P h a r m l N o n P s i o a h a a h a n s r m r m a a S t o 3 6 3 4 1 4 r e 3 2 0 2 3 5 4 2 1 2 8 1 s 1 2 # F Y 2 7 1 3 , 7 1 , 5 8 1 , 0 1 1 1 7 , 4 F Y 2 7 9 , 6 1 , 2 1 , 6 1 , 2 1 3 , 7 Q 2 2 7 2 3 3 0 Q 4 1 0 7 2 1 9 1 1 4 1 1 9 1 1 4 0 3 9 . 4 . 3 . 6 . 5 . 2 . 5 . 3 . 1 . 5 . 1 . 7 . 4 N N e t R e v e F Y 2 6 Q 1 2 , 2 3 6 1 , 1 9 6 6 0 1 2 6 - 6 7 0 1 4 , 7 3 1 e t R e v e F Y 2 6 Q 8 , 4 1 7 1 , 1 3 3 1 , 6 3 6 1 , 0 4 9 1 2 , 2 3 6 n u 1 . 9 . 9 . 0 . 2 . 0 . 0 n u 1 . 2 . 9 . 3 . 5 . 9 e e F Y 2 6 Q 1 3 , 9 2 8 1 , 5 1 4 8 6 0 7 2 0 - 3 0 2 1 7 , 3 2 6 F Y 2 6 Q 9 , 5 1 5 1 , 2 3 0 1 , 7 1 0 1 , 4 7 1 1 3 , 9 2 8 4 . 1 . 8 . 4 . 2 . 6 . 2 4 . 0 . 7 . 7 . 7 . 1 Y o Y 1 , 4 9 3 2 2 7 9 9 1 3 - 5 3 2 , 6 7 Y o Y 1 , 2 2 8 ( 3 2 2 1 , 4 9 2 4 0 8 1 8 8 4 0 6 4 2 . 5 . 3 . 6 . 3 . 2 . 6 . 3 . 0 . 6 . 3 . 2 . 5 ) Y Y N e t o Y % 1 2 2 7 4 5 3 8 1 6 - 8 0 1 8 . 2 N e t o Y % 1 4 . 5 7 . 1 - 2 . 2 2 1 . 4 1 2 . 2 G % % % % % % G % % % % % r r o o w t h Q o Q - 1 9 8 . 6 . 1 1 . 3 0 4 . 1 3 1 . - 1 7 1 . 8 3 . w t h Q o Q 1 2 6 ( 1 6 ( 1 1 0 ( 1 9 8 ( 1 9 8 7 4 2 2 1 1 1 . . . . . 8 8 0 7 7 7 7 1 2 7 1 8 ) ) ) ) Q Q o Q - 1 0 1 4 2 - 5 6 0 o Q 1 - 1 - 6 - 1 3 - 1 % . 4 . 4 . 3 . 2 . 6 . 5 % . 3 . 3 . 5 . 5 . 4 % % % % % % % % % % % KPIs’ by Cohort: New Stores Revenue Ramp up FY26 & FY27 Cohort Stores# Month-1 Month-3 Month-6 Month-9 Month-12 Month-15 Apr-25 18 1 7,596 1 4,484 19,174 2 3,660 25,272 25,714 May-25 15 1 4,591 2 3,613 32,317 3 6,965 37,793 Jun-25 39 6,454 1 7,241 23,076 2 5,137 24,612 Jul-25 16 2 9,452 1 7,846 25,574 2 8,581 29,529 Aug-25 18 1 0,827 1 6,228 20,473 2 1,248 Sep-25 49 1 5,466 1 9,659 25,629 2 6,396 Oct-25 19 1 6,133 2 1,123 27,826 3 1,855 Nov-25 39 9,425 1 7,636 20,804 Dec-25 61 1 5,615 2 1,394 27,903 Jan-26 52 2 3,059 2 2,333 27,745 Feb-26 59 1 9,004 2 2,051 Mar-26 57 1 7,487 2 0,992 Apr-26 41 2 7,988 2 9,437 May-26 33 2 4,463 Jun-26 38 3 6,115 FY27 112 29,707 29,437 FY26 442 16,507 20,079 25,321 27,050 27,823 25,714 FY25 336 12,245 14,819 19,509 22,131 24,453 25,917 FY24 659 8 ,985 13,144 17,961 20,033 21,013 21,557 FY23 1141 7 ,190 12,456 17,189 19,859 21,626 22,878 12 KPIs’ by Cohort: FY26 & FY27 – SL EBITDA% Ramp up Cohort Stores# Month-3 Month-6 Month-9 Month-12 Month-15 Apr-25 18 -4.6% 3.3% 7.4% 10.9% 7.5% May-25 15 1.4% 8.1% 10.1% 8.8% Jun-25 39 -2.2% 5.0% 5.8% 4.2% Jul-25 16 -6.0% 3.4% 8.3% 3.2% Aug-25 18 -3.0% 1.9% 1.1% Sep-25 49 -1.4% 4.0% 5.1% Oct-25 19 -2.6% 6.5% 4.4% Nov-25 39 -2.3% 1.5% Dec-25 61 -5.2% 1.1% Jan-26 52 2.1% 2.2% Feb-26 59 -4.1% Mar-26 57 -4.5% Apr-26 41 -1.2% May-26 33 Jun-26 38 FY27 112 -1.2% FY26 442 -2.6% 3.2% 6.0% 6.3% 7.5% FY25 336 -5.2% 2.4% 5.4% 6.8% 8.1% FY24 659 -2.7% 3.3% 5.8% 6.4% 7.3% FY23 1141 -3.8% 2.4% 4.3% 5.3% 6.3% 13 Income Statement Diagnostics ₹m Q1 FY27 AOP Particulars Q1 FY27 Q1 FY26 Q4 FY26 YoY QoQ AOP Variance Revenue 370.8 302.9 347.8 368.1 22.4% 6.6% 0.7% Cost of Material Consumed 66.7 57.7 62.2 67.8 15.6% 7.1% -1.7% Center Level Expenses 183.3 153.8 177.2 186.3 19.2% 3.5% -1.6% Salaries 64.0 47.4 62.2 65.3 35.1% 2.9% -2.0% Rent 32.4 26.0 31.8 31.7 24.3% 1.9% 2.0% Others 86.9 80.4 83.2 89.2 8.1% 4.5% -2.5% Center Level EBITDA 120.8 91.4 108.4 114.0 32.1% 11.4% 5.9% Center Level EBITDA% 32.6% 30.2% 31.2% 31.0% 2.4% 1.4% 1.6% Central Lab Opex 30.4 28.1 30.2 39.5 8.4% 0.8% -22.9% Center Level EBITDA after 90.3 63.3 78.2 74.6 42.6% 15.5% 21.2% Central Lab Opex Center Level EBITDA% 24.4% 20.9% 22.5% 20.3% 3.5% 1.9% 4.1% Other Expenses 24.4 22.0 25.1 31.5 10.9% -2.6% -22.4% Corporate 21.5 18.9 21.6 25.9 13.5% -0.6% -17.0% Marketing 3 .3 3 .8 3 .8 5 .0 -12.0% -11.6% -33.4% Others (0.4) (0.7) (0.3) 0 .6 -41.8% 26.7% -175.6% Operating EBITDA 65.9 41.3 53.1 43.1 59.5% 24.1% 53.0% Operating EBITDA% 17.8% 13.6% 15.3% 11.7% 4.1% 2.5% 6.1% Depreciation 34.7 34.7 35.1 37.6 0.0% -1.0% -7.7% Operating EBIT 31.2 6 .6 18.1 5 .5 372.5% 72.8% 472.3% Operating EBIT% 8.4% 2.2% 5.2% 1.5% 6.2% 3.2% 6.9% 15 Capex AOP vs Actual ₹ million Particulars FY27 FY27 Q1 FY27 Q1 AOP AOP Actual New COCO Stores 700.0 145.0 126.3 New FOFO Stores 400.0 100.0 New Warehouses 80.0 80.0 26.6 Stores Renovation 500.0 125.0 14.7 Maintenance Capex (Optival) 120.0 30.0 153.6 Factories Capex (Optival) 5.0 1.3 - Factories Capex (Medplus) 5.0 1.3 4.6 Surgical factory additional machinery 3.6 3.6 - Diagnostics Bangalore Processing Lab 55.0 55.0 - Standalone Collection Centers 104.0 6.4 12.7 Maintenance Capex (Medplus) 5.0 1.3 Total 1,977.6 548.8 338.4 17 Performance vs AOP (Summary) Actuals AOP Achievement Particulars Q1 FY27 FY27 Q1 FY27 Q2 FY27 Q3 FY27 Q4 FY27 FY27 Q1 FY27 Q2 FY27 Q3 FY27 Q4 FY27 FY27 Revenue 18,796 18,796 18,993 20,797 21,955 22,546 84,290 99.0% 0.0% 0.0% 0.0% 22.3% d e Shoplevel Expenses 2,696 2,696 2,818 2,919 3,036 3,139 11,912 95.7% 0.0% 0.0% 0.0% 22.6% t a Shoplevel EBITDA 1,907 1,907 2,096 2,446 2,594 2,639 9,776 91.0% 0.0% 0.0% 0.0% 19.5% d i Shoplevel EBITDA% 10.1% 10.1% 11.0% 11.8% 11.8% 11.7% 11.6% l o s Other Expenses 1,256 1,256 1,298 1,339 1,362 1,376 5,375 96.8% 0.0% 0.0% 0.0% 23.4% n o Operating EBITDA 6 51 6 51 7 98 1,106 1,232 1,263 4,400 81.6% 0.0% 0.0% 0.0% 14.8% C Operating EBITDA% 3.5% 3.5% 4.2% 5.3% 5.6% 5.6% 5.2% Revenue 18,399 18,399 18,600 20,369 21,524 22,071 82,564 98.9% 0.0% 0.0% 0.0% 22.3% Shoplevel Expenses 2,498 2,498 2,616 2,711 2,811 2,894 11,033 95.5% 0.0% 0.0% 0.0% 22.6% y c a Shoplevel EBITDA 1,784 1,784 1,981 2,310 2,473 2,502 9,265 90.1% 0.0% 0.0% 0.0% 19.3% m Shoplevel EBITDA% 9.7% 9.7% 10.7% 11.3% 11.5% 11.3% 11.2% r a Other Expenses 1,196 1,196 1,221 1,258 1,278 1,293 5,050 98.0% 0.0% 0.0% 0.0% 23.7% h P Operating EBITDA 5 88 5 88 7 60 1,051 1,194 1,209 4,215 77.3% 0.0% 0.0% 0.0% 14.0% Operating EBITDA% 3.2% 3.2% 4.1% 5.2% 5.5% 5.5% 5.1% Revenue 3 71 3 71 3 68 3 99 4 07 4 46 1,620 100.7% 0.0% 0.0% 0.0% 22.9% s Center Level Expenses 1 83 1 83 1 86 1 93 2 09 2 30 8 18 98.4% 0.0% 0.0% 0.0% 22.4% c i t Center Level EBITDA 1 21 1 21 1 14 1 33 1 22 1 34 5 04 105.9% 0.0% 0.0% 0.0% 24.0% s o Center Level EBITDA% 32.6% 32.6% 31.0% 33.3% 30.1% 30.1% 31.1% n g Other Expenses 55 55 71 75 77 77 3 00 77.3% 0.0% 0.0% 0.0% 18.3% a i D Operating EBITDA 66 66 43 58 45 57 2 04 153.0% 0.0% 0.0% 0.0% 32.3% Operating EBITDA% 17.8% 17.8% 11.7% 14.6% 11.1% 12.8% 12.6% Revenue 27 27 26 28 24 28 1 06 102.8% 0.0% 0.0% 0.0% 25.0% Shoplevel Expenses 14 14 15 15 15 15 62 94.6% 0.0% 0.0% 0.0% 23.5% s Shoplevel EBITDA 3 3 1 3 (1) 3 7 248.4% 0.0% 0.0% 0.0% 37.3% r e h Shoplevel EBITDA% 9.5% 9.5% 3.9% 10.8% -2.3% 11.6% 6.3% t O Other Expenses 5 5 6 6 7 7 26 82.9% 0.0% 0.0% 0.0% 20.5% Operating EBITDA (3) (3) (5) (3) (7) (3) (19) 51.9% 0.0% 0.0% 0.0% 14.6% Operating EBITDA% -10.6% -10.6% -20.9% -12.1% -29.4% -11.6% -18.1% 20 KPIs’ : Sales per day per store ₹ Days of Inventory 43,762 45,582 44,944 94 98 40,608 39,846 41,151 94 38,849 38,765 76 28,506 27,235 27,355 70 25,731 73 23,320 63 63 20,983 21,152 21,268 21,427 28,399 61 26,542 27,219 23,228 21,107 23,284 25,471 51 51 18,100 19,615 18,219 46 47 45 16,015 14,081 40 42 41 11,920 43 38 38 37 35 34 34 33 FY25Q2 FY25Q3 FY25Q4 FY26Q1 FY26Q2 FY26Q3 FY26Q4 FY27Q1 FY25Q2 FY25Q3 FY25Q4 FY26Q1 FY26Q2 FY26Q3 FY26Q4 FY27Q1 Upto FY23 FY24 FY25 FY26 FY27 Upto FY23 FY24 FY25 FY26 FY27 Shop level EBITDA % 17 15 13.5 12.7 13 10.3 11.1 11.8 11.2 12.2 10.5 11.5 10.8 11 9.3 9.3 9.3 9 7.4 8.3 7.9 8.0 7.1 7 6.2 6.1 5 2.6 3 1 0.1 0.7 1.9 -1 FY25Q2 FY25Q3 FY25Q4 FY26Q1 -24.8 FY26Q2 -5.0 FY26Q3 -0.8 FY26Q4 FY27Q1 -3 -5 -3.6 Upto FY23 FY24 FY25 FY26 21 Diagnostic Center wise Income Statement ₹m – Q1FY27 Hyd Hyderabad Chennai Srinagar Vijaynagar Vanasthalipu Particulars Gachibowli Habsiguda Kompally Kukatpally Nallagandla Dilsukhnagar Miyapur Banjara Hills AS Rao Nagar Standalone Collection Collection Total Colony Colony ram CCs centers centers No of Months in Operation 51 47 42 37 41 40 39 38 38 38 38 33 Revenue 40.0 38.3 33.4 36.0 14.2 15.1 14.2 3.8 4.6 8.1 5.5 10.3 56.0 28.3 1.9 309.8 Subscription Revenue 4.6 8.0 7.8 4.3 3.0 4 .0 3.9 1.0 0.6 2.5 1.4 2 .5 10.2 6.7 0.5 61.0 Total Revenue 4 4.6 46.4 41.2 40.3 17.2 19.0 18.0 4.8 5.2 1 0.5 7.0 12.8 66.2 35.0 2.4 370.8 Cost of Material Consumed 7.1 6.3 6.0 6.3 3.2 2 .6 3.1 0.8 1.1 1.9 1.3 2 .2 16.6 7.6 0.5 66.7 Center Level Opex 22.2 20.7 19.3 19.0 9.4 14.3 7.5 4.3 3.8 5.6 5.4 6 .2 32.4 8.7 4.5 183.3 Center Level EBITDA 15.4 19.4 16.0 15.1 4.6 2 .1 7.4 ( 0.4) 0 .2 3.0 0.3 4 .4 17.2 18.7 (2.7) 120.8 Central Lab Opex 2.7 1.9 2.3 2.2 1.5 1 .0 1.5 0.4 0.5 0.8 0.5 1 .0 8.3 4.2 1.5 30.4 Center Level EBITDA after Central Lab Opex 1 2.7 17.5 13.7 12.9 3.1 1 .1 6.0 ( 0.8) (0.3) 2 .2 ( 0.3) 3 .4 8.9 14.5 (4.2) 9 0.3 Marketing Expenses 0.4 0.4 0.4 0.4 0.2 0 .2 0.2 0.0 0.0 0.1 0.1 0 .1 0.6 0.3 0.0 3 .3 Diagnostic Corporate Expenses 2.5 2.4 2.1 2.3 0.9 0 .9 0.9 0.2 0.3 0.5 0.3 0 .6 3.5 1.8 0.1 19.4 Pre operative expenses - - - - - - - - - - - - 0.4 - 1.3 1 .7 EBITDA 9.7 1 4.7 11.2 10.2 2.1 ( 0.0) 4.9 ( 1.1) (0.6) 1 .6 ( 0.7) 2 .6 4.4 12.4 (5.6) 6 5.9 Depreciation 5.1 4.7 5.0 4.7 1.9 1 .4 1.4 0.7 0.8 1.2 0.9 1 .7 3.7 1.0 0.4 34.7 EBIT 4.7 1 0.0 6.2 5.5 0.1 ( 1.4) 3.5 ( 1.8) (1.4) 0 .4 ( 1.6) 0 .9 0.6 11.5 (6.0) 3 1.2 22